Main menu


A pharmaceutical company in a statement to the stock exchange: an agreement to produce more than 40 million doses of Sputnik vaccine annually

MENA Pharm Pharmaceutical and Chemical Industries announced, in a statement to the Egyptian Stock Exchange, today, Thursday, the signing of a contract with the Russian Direct Investment Fund to transfer DNA technology through manufacturing using genetic engineering with its subsidiary, Probiogen AG, on an agreement to produce more than 40 million doses annually. One of the world's first recorded vaccines against Covid 19 is the Sputnik V vaccine.

The company said that the first stage is the stage of technology transfer and the approval of the Ministry of Health, the Egyptian Drug Authority and the Ministry of Health committees, and it is expected to start pre-launch trials for vaccine production in the third quarter of 2021, noting that the financial and commercial contract has not been signed.


Mina Pharm pharmaceutical company indicated that the effectiveness of Sputnik V is 97.6%, based on the analysis of data on the rate of infection with the Coronavirus among those in Russia who were vaccinated with this vaccine.